Ned Feder, M.D.

The Food and Drug Administration has a brand-new policy bringing greater transparency regarding the agency's advisory committee members. The increased transparency will help address concerns over these members' conflicts of interest and the advice they give on drug and medical...

Patients’ health is put at risk when outside experts advising the FDA have private financial interests that are undisclosed to the public. We propose specific ways to start correcting the problem. In short: POGO to FDA on conflicts of interest: Disclose them!

POGO questions if FDA is dealing well with conflicts of interest on FDA advisory committees.

We are writing about the failure by senior government officials to comply with an Executive Order that requires transparency in certain operations of the Office of Management and Budget (OMB) and the Office of Information and Regulatory Affairs (OIRA). The requirements for tra...

Since its creation thirty years ago, the Project On Government Oversight (POGO), a nonprofit, nonpartisan organization, has identified instances of financial conflicts of interest in the federal government and successfully pressed to correct them. We recently learned of indust...

We are writing with concerns about Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at the FDA.